Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1619-1624

  Davis, Paul J ^a,b   Lin, Hung Yun ^b,c   Sudha, Thangirala ^b   Yalcin, Murat ^b,d   Tang, Heng Yuan ^b   Hercbergs, Aleck ^e   Leith, John T ^f   Luidens, Mary K ^a   Ashur Fabian, Osnat ^g,h   Incerpi, Sandra ⁱ   Mousa, Shaker A ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d ULUDAG UNIVERSITY   (Turkey)

^e LERNER RESEARCH INSTITUTE   (United States)

^f Rhode island Nuclear Science Center   (United States)

^g MEIR MEDICAL CENTER   (Israel)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ ROMA TRE UNIVERSITY   (Italy)

Author keywords

Antiangiogenesis; Integrin; Proapoptosis; Thyroid hormone; Thyroxine

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; BETA3 INTEGRIN; CATENIN; CD51 ANTIGEN; CYCLINE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; NANOTETRAC; PROTEIN BCL X; THROMBOSPONDIN 1; THYROID HORMONE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VITRONECTIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; DNA STRAND BREAKAGE; DOWN REGULATION; DRUG EFFECT; EGFR GENE; FIBROBLAST; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; INTERNALIZATION; MMP 9 GENE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; RADIOSENSITIZATION; REVIEW; TSP1 GENE; TUMOR CELL; UPREGULATION; VEGFA GENE;

EID: 84907217881     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S67393     Document Type: Review

References (52)

1. Goodman AD, Hoekstra SJ, Mars PS. Effects of hypothyroid-ism on the induction and growth of mammary cancer induced by 7,12-dimethylbenz(a)anthracene in the rat. Cancer Res. 1980;40(7): 2336–2342.
2. Borek C, Guernsey DL, Ong A, Edelman IS. Critical role played by thyroid hormone in induction of neoplastic transformation by chemical carcinogens in tissue culture. Proc Natl Acad Sci U S A. 1983;80(18): 5749–5752.
3. Hall LC, Salazar E P, Kane SR, Liu N. Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol. 2008;109(1–2):57–66.
4. Cohen K, Ellis M, Khoury S, Davis PJ, Hercbergs A, Ashur-Fabian O. Thyroid hormone is a MAPK-dependent growth factors for human myeloma cells acting via αvβ3 integrin. Mol Cancer Res. 2011;9(10): 1385–1394.
5. Meng R, Tang HY, Westfall J, et al. Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung cancer cells. PLoS One. 2011; 6(11):e27547.
6. Lin H Y, Tang H Y, Shih A, et al. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids. 2007;72(2):180–187.
7. Davis FB, Lin HY, Shih A, et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res. 2006;66(14):7270-7275.
8. Davis FB, Mousa SA, O’Connor L, et al. Proangiogenic action of thyroid hormone is fbroblast growth factor-dependent and is initiated at the cell surface. Circ Res. 2004;94(11):1500-1506.
9. Bergh JJ, Lin HY, Lansing L, et al. Integrin alphavbeta3 contains a cell surface receptor for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology. 2005;146(7):2864-2871.
10. Liu X, Zheng N, Shi YN, Yuan J, Li L. Thyroid hormone induced angiogenesis through integrin av|53/protein kinase D/histone acetylase 5 signaling pathway. J Mol Endocrinol. 2014;52(3):245-254.
11. Chen J, Ortmeier SB, Savinova OV, et al. Thyroid hormone induces sprouting angiogenesis in adult heart of hypothyroid mice through the PDGF-Akt pathway. J Cell Mol Med. 2012;16(11): 2726-2735.
12. Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol. 2011;51:99–115.
13. Luidens MK, Mousa S A, Davis FB, Lin HY, Davis PJ. Thyroid hormone and angiogenesis. Vascul Pharmacol. 2010;52(304):142-145.
14. Hercbergs AA, Goyal LK, Suh JH, et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a Phase I/II trial. Anticancer Res. 2003;23(1B):617-626.
15. Cristofanilli M, Yamamura Y, Kau SW, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005;103(6): 1122-1128.
16. Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. 2011;117(3): 534-544.
17. Nelson M, Hercbergs A, Rybicki L, Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006;132(10): 1041-1046.
18. Hercbergs AH, Ashur-Fabian O, Garfeld D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Current Opin Endocrinol Diabetes Obes. 2011;17(5):432–436.
19. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem. 2000;275(29):21785-21788.
20. Lin HY, Lansing L, Merillon JM, et al. Integrin alphavbeta3 contains a receptor site for resveratrol. FASEB J. 2006;20(10):1742-1744.
21. Lin HY, Sun M, Lin C, et al. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J Steroid Biochem Mol Biol. 2009;113(3-5):182-188.
22. Zhou X, Murphy FR, Gehdu N, Zhang J, Iredale JP, Benyon RC. Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem. 2004;279(23): 23996-24006.
23. Stefansson S, Su EJ, Ishigami S, et al. The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin. J Biol Chem. 2007;282(21):15679-15689.
24. Leonard JL, Farwell AP. Thyroid hormone-regulated actin polymerization in brain. Thyroid. 1997;7(1):147-151.
25. Farwell AP, Dubord-Tomasetti SA, Pietrzykowski AZ, Stachelek SJ, Leonard JL. Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3',5'-triiodothyronine. Brain Res Dev Brain Res. 2005;154(1):121-135.
26. Cohen K, Ellis M, Shindeman E, Khoury S, Davis PJ, Hercbergs A, Ashur-Fabian O. Relevance of thyroid hormones-alphavbeta3 pathway in primary myeloma to bortezomib action. Leuk Lymphoma. 2014;20:1-8.
27. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010;31(2):139–170.
28. Moreno M, De Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F. Metabolic effects of thyroid hormone derivatives. Thyroid. 2008;18(2): 239–253.
29. Lin HY, Cody V, Davis FB, et al. Identifcation and functions of the plasma membrane receptor for thyroid hormone analogues. Discov Med. 2011;11(59):337–347.
30. Mousa SA, O’Connor L, Davis FB, Davis PJ. Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin-mediated. Endocrinology. 2006;147(4):1602–1607.
31. Lin HY, Sun M, Tang H Y, et al. L-thyroxine vs 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol. 2009;296(5):C980–C991.
32. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova T V. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res. 2007;101(6):570–580.
33. Mousa SA, Bergh JJ, Dier E, et al. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fbroblast growth factor. Angiogenesis. 2008;11(2):183–190.
34. Mousa SA, Lin HY, Tang HY, Hercbergs A, Luidens MK, Davis PJ. Modulation of angiogenesis by thyroid hormone and hormone analogues: implications for cancer management. Angiogenesis. 2014;17(3):463–469.
35. Yu CH, Law JB, Suryana M, Low H Y, Sheetz M P. Early integrin binding to Arg-Gly-Asp peptide activates actin polymerization and contractile movement that stimulates outward translocation. Proc Natl Acad Sci U S A. 2011;108(51):20585–20590.
36. Savinova O V, Liu Y, Aasen GA, et al. Thyroid hormone promotes remodeling of coronary resistance vessels. PLoS One. 2011;6(9):e25054.
37. Glinskii AB, Glinsky G V, Lin HY, et al. Modifcation of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle. 2009;8(21):3562–3570.
38. Yalcin M, Dyskin E, Lansing L, et al. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 2010;95(4):1972–1980.
39. Yalcin M, Lin HY, Sudha T, et al. Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Horm Cancer. 2013;4(3):176–185.
40. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33(4):369–385.
41. Sarfati M, Fortin G, Raymond M, Susin S. CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. Curr Drug Targets. 2008;9(10):842–850.
42. Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32:25–50.
43. Rae MT, Gubbay O, Kostogiannou Price D, Critchley HO, Hillier SG. Thyroid hormone signaling in human ovarian surface epithelial cells. J Clin Endocrinol Metab. 2007;92(1):322–327.
44. Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloprotei-nases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 2013;34(4):2041–2051.
45. Lin HY, Su Y F, Hsieh MT, et al. Nuclear monomeric integrin αv in cancer cells is a coactivator regulated by thyroid hormone. FASEB J. 2013;27(8):3209–3216.
46. Roberts MS, Woods AJ, Dale TC, Van Der Sluijs P, Norman JC. Protein kinase B/Akt acts via glycogen synthase kinase 3 to regulate recycling of alpha v beta 3 and alpha 5 beta 1 integrins. Mol Cell Biol. 2004;24(4):1505–1515.
47. Hercbergs A, Davis PJ, Davis FB, Ciesielski MJ, Leith JT. Radiosensitization of GL261 glioma cells by tetraiodothyroacetic acid (tetrac). Cell Cycle. 2009;8(16):2586–2591.
48. Hercbergs AH, Lin H Y, Davis FB, Davis PJ, Leith JT. Radiosensitization and production of DNA double-strand breaks in U87MG brain tumor cells induced by tetraiodothyroacetic acid (tetrac). Cell Cycle. 2011;10(2):352–357.
49. Mousa SA, Thangirala S, Yalcin M, et al. Actions of nanoparticulate tetraiodothyroacetic acid (Nanotetrac) on human prostate carcinoma xenograft growth, vascularity and integrin response to radiation. Annual Meeting of the American Association for Cancer Research; April 9, 2014; San Diego, CA, USA. Abstract 5378.
50. Shih A, Lin HY, Davis FB, Davis PJ. Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. Biochemistry. 2001;40(9):2870–2878.
51. Shih A, Zhang S, Cao HJ, et al. Disparate effects of thyroid hormone on actions of epidermal growth factor and transforming growth factor-α are mediated by 3′,5′-cyclic adenosine 5’-monophosphate-dependent protein kinase II. Endocrinology. 2004;145(4):1708–1717.
52. Bharali DJ, Yalcin M, Davis PJ, Mousa SA. Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (Lond). 2013;8(12): 1943–1954.